Isomyosmine clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses isomyosmine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
MyMD Pharmaceuticals, Inc. (2) · TNF Pharmaceuticals, Inc. (1)
Studies
Open first, then newest update. How each study uses isomyosmine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/FrailtyCompletedPhase 2TNF Pharmaceuticals, Inc.NCT05283486Written as MYMD-1 600MG
- Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult SubjectsCompletedPhase 1MyMD Pharmaceuticals, Inc.NCT05077865Written as MYMD-1
- Single Ascending-dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male Adult SubjectsCompletedPhase 1MyMD Pharmaceuticals, Inc.NCT04349761Written as MyMD1